What is the mechanism of action (MOA) for Otezla^® (apremilast) in psoriatic arthritis?

OTEZLA IS A NON-BIOLOGIC ORAL PDE4 INHIBITOR WITH A DISTINCT MOA FOR THE TREATMENT OF ADULT PATIENTS WITH PSORIATIC ARTHRITIS.¹

Otezla works by inhibiting phosphodiesterase 4 (PDE4) intracellularly and has anti-inflammatory properties.^1-4 By elevating cyclic adenosine monophosphate (cAMP) levels, Otezla is thought to indirectly modulate production of pro-inflammatory and anti-inflammatory mediators.^2,3

PDE4 and cAMP

Learn more about the role of phosphodiesterase 4 (PDE4) and cAMP in controlling inflammation.^2-4

Otezla MOA

Learn how Otezla’s inhibition of PDE4 within cells affects the production of inflammatory mediators.^1,3,4

The specific mechanism(s) by which Otezla exerts its therapeutic action in psoriatic arthritis are not well defined.¹